TherapeuticsMD Inc. (NASDAQ:TXMD) has a beta value of 1.88 and has seen 4.77 million shares traded in the last trading session. The company, currently valued at $362.70M, closed the last trade at $0.80 per share which meant it lost -$0.06 on the day or -7.12% during that session. The TXMD stock price is -243.75% off its 52-week high price of $2.75 and 11.25% above the 52-week low of $0.71. If we look at the company’s 10-day average daily trading volume, we find that it stood at 5.39 million shares traded. The 3-month trading volume is 5.72 million shares.
The consensus among analysts is that TherapeuticsMD Inc. (TXMD) is a Buy stock at the moment, with a recommendation rating of 1.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.11.
TherapeuticsMD Inc. (NASDAQ:TXMD) trade information
Sporting -7.12% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Friday, 09/03/21 when the TXMD stock price touched $0.80 or saw a rise of 6.98%. Year-to-date, TherapeuticsMD Inc. shares have moved -34.30%, while the 5-day performance has seen it change -1.65%. Over the past 30 days, the shares of TherapeuticsMD Inc. (NASDAQ:TXMD) have changed -15.68%. Short interest in the company has seen 32.34 million shares shorted with days to cover at 5.72.
Wall Street analysts have a consensus price target for the stock at $4.75, which means that the shares’ value could jump 83.16% from current levels. The projected low price target is $4.00 while the price target rests at a high of $5.00. In that case, then, we find that the current price level is -525.0% off the targeted high while a plunge would see the stock gain -400.0% from current levels.
TherapeuticsMD Inc. (TXMD) estimates and forecasts
Figures show that TherapeuticsMD Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -41.11% over the past 6 months, with this year growth rate of 43.06%, compared to 18.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 42.10% and 16.70% for the next quarter. Revenue growth from the last financial year stood is estimated to be 50.80%.
4 analysts offering their estimates for the company have set an average revenue estimate of $23 million for the current quarter. 4 have an estimated revenue figure of $25.87 million for the next quarter concluding in Sep 2021.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -6.30% over the past 5 years. Earnings growth for 2021 is a modest 6.90% while over the next 5 years, the company’s earnings are expected to increase by 17.60%.
TherapeuticsMD Inc. is expected to release its next earnings report on May 06 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
TherapeuticsMD Inc. (NASDAQ:TXMD)’s Major holders
Insiders own 8.02% of the company shares, while shares held by institutions stand at 46.20% with a share float percentage of 50.23%. Investors are also buoyed by the number of investors in a company, with TherapeuticsMD Inc. having a total of 215 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 24.84 million shares worth more than $29.56 million. As of Jun 29, 2021, Blackrock Inc. held 5.86% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 18.61 million shares as of Jun 29, 2021. The firm’s total holdings are worth over $22.15 million and represent 4.39% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Mar 30, 2021, the former fund manager holds about 2.25% shares in the company for having 9.54 million shares of worth $12.78 million while later fund manager owns 8.32 million shares of worth $9.9 million as of Jun 29, 2021, which makes it owner of about 1.96% of company’s outstanding stock.